Author: David Cooper

Downloads per author, site-wide

Preprints

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

• Downloaded 67,370 times
• Download rankings, all-time:
  • Site-wide: 75
  • In infectious diseases: 30
• Year to date:
  • Site-wide: 214
• Since beginning of last month:
  • Site-wide: 321

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

• Downloaded 63,902 times
• Download rankings, all-time:
  • Site-wide: 83
  • In infectious diseases: 32
• Year to date:
  • Site-wide: 74
• Since beginning of last month:
  • Site-wide: 136

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

• Downloaded 55,739 times
• Download rankings, all-time:
  • Site-wide: 96
  • In microbiology: 8
• Year to date:
  • Site-wide: 5
• Since beginning of last month:
  • Site-wide: 127

Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera

• Downloaded 30,531 times
• Download rankings, all-time:
  • Site-wide: 208
  • In microbiology: 19
• Year to date:
  • Site-wide: 19
• Since beginning of last month:
  • Site-wide: 32

Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine

• Downloaded 22,729 times
• Download rankings, all-time:
  • Site-wide: 296
  • In infectious diseases: 110
• Year to date:
  • Site-wide: 432
• Since beginning of last month:
  • Site-wide: 479

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

• Downloaded 12,060 times
• Download rankings, all-time:
  • Site-wide: 626
  • In infectious diseases: 203
• Year to date:
  • Site-wide: 104
• Since beginning of last month:
  • Site-wide: 182